TheiaNova

TheiaNova is a New Zealand-based biotechnology company specializing in regenerative medicine for ophthalmology, with a primary focus on treating keratoconus. Spun out from the University of Auckland, the company is developing a proprietary pharmacological therapy, TN-001, designed to stimulate the eye's natural mechanisms for collagen production and reorganization. By strengthening the corneal structure through biochemical pathways rather than surgical intervention, TheiaNova aims to provide a non-invasive alternative to traditional treatments like corneal cross-linking. The company's research leverages insights into growth factor signaling to restore corneal thickness and prevent the progression of vision loss.